Are you Dr. Nada?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 31 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1901 W Harrison St
Chicago, IL 60612Phone+1 312-864-6500- Is this information wrong?
Summary
- Dr. Adel Nada, MD is an internist in Chicago, Illinois. He is currently licensed to practice medicine in Illinois.
Education & Training
- Cook County Health and Hospitals SystemResidency, Internal Medicine, 1997 - 2000
- University of Alexandria Faculty of MedicineClass of 1994
Certifications & Licensure
- IL State Medical License 1999 - 2026
Publications & Presentations
PubMed
- Harnessing regulatory T cells to establish immune tolerance.Patrick Ho, Ellen Cahir-McFarland, Jason D Fontenot, Tracey Lodie, Adel Nada, Qizhi Tang, Laurence A Turka, Jeffrey A Bluestone> ;Science Translational Medicine. 2024 Mar 13
- 94 citationsThe RENEW Trial: Efficacy and Safety of Intramyocardial Autologous CD34(+) Cell Administration in Patients With Refractory Angina.Thomas J. Povsic, Timothy D. Henry, Jay H. Traverse, F. David Fortuin, Gary L. Schaer, Dean J. Kereiakes, Richard A. Schatz, Andreas M. Zeiher, Christopher J. White, D...> ;JACC. Cardiovascular Interventions. 2016 Aug 8
- 13 citationsStudying navitoclax, a targeted anticancer drug, in healthy volunteers--ethical considerations and risk/benefit assessments and management.Hao Xiong, Rajendra Pradhan, Adel Nada, Andrew Krivoshik, Kyle D. Holen, James W. Rhodes, Gary Gordon, Rod A. Humerickhouse, Walid M. Awni> ;Anticancer Research. 2014 Jul 1
- Join now to see all
Press Mentions
- GentiBio Nets $157 Million to Restore Immune Tolerance with TregsAugust 11th, 2021
- GentiBio Launches with $20M Seed Funding to Develop Engineered Regulatory T Cells for Autoimmune and Inflammatory DiseasesAugust 7th, 2020
- Start-up to Engineer T-cells for Autoimmune DiseasesAugust 6th, 2020
- Join now to see all